GlucoTrack submits IDE application to initiate study for CBGM technology

Glucotrack (GCTK) submitted its Investigational Device Exemption application to the U.S. Food and Drug Administration to initiate a US clinical study for its fully implantable continuous blood glucose monitoring technology. “Submission of our IDE represents meaningful progress in the development of our CBGM technology and underscores our commitment to helping people with diabetes live more fully,” said Paul Goode, CEO. “Our fully implantable solution is designed to be comfortable and discreet so that people can focus on their daily lives – allowing them to work, exercise, sleep, and socialize without the disruption of frequent sensor changes, visible wearables, or reordering supplies. We look forward to generating the clinical data needed to advance toward regulatory approval and demonstrate that continuous glucose monitoring can be both highly accurate and virtually invisible.”